Biomedical Engineering Society and FDA Frontiers in Medical Devices: Innovations in Modeling and Simulation, 17757-17758 [2015-07551]
Download as PDF
Federal Register / Vol. 80, No. 63 / Thursday, April 2, 2015 / Notices
Commission, Office of the Secretary,
600 Pennsylvania Avenue NW., Suite
CC–5610 (Annex J), or deliver your
comment to the following address:
Federal Trade Commission, Office of the
Secretary, Constitution Center, 400 7th
Street SW., 5th Floor, Suite 5610
(Annex J), Washington, DC 20024. If
possible, submit your paper comment to
the Commission by courier or overnight
service.
The FTC Act and other laws that the
Commission administers permit the
collection of public comments to
consider and use in this proceeding as
appropriate. The Commission will
consider all timely and responsive
public comments that it receives on or
before June 1, 2015. For information on
the Commission’s privacy policy,
including routine uses permitted by the
Privacy Act, see https://www.ftc.gov/ftc/
privacy.htm.
David C. Shonka,
Principal Deputy General Counsel.
[FR Doc. 2015–07552 Filed 4–1–15; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Solicitation of Written Comments on
Draft National Pain Strategy
The National Institute of
Neurological Disorders and Stroke
(NINDS) Office of Pain Policy is
soliciting public comment on the draft
National Pain Strategy.
DATES: Comments on the draft National
Pain Strategy must be received no later
than 5 p.m. EST on May 20, 2015.
ADDRESSES: The draft National Pain
Strategy is available at: https://
iprcc.nih.gov/docs/
DraftHHSNationalPainStrategy.pdf.
Written comments sent electronically
are preferred and may be addressed to
NPSPublicComments@NIH.gov. Written
responses should be addressed to Linda
Porter, Ph.D., NINDS/NIH, 31 Center
Drive, Room 8A31, Bethesda, MD
20892.
SUMMARY:
tkelley on DSK3SPTVN1PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Contact Linda Porter, Ph.D., NINDS/
NIH, 31 Center Drive, Room 8A31,
Bethesda, MD 20892,
porterl@ninds.nih.gov.
The draft
National Pain Strategy reflects the work
of many offices across the Department of
Health and Human Services,
Department of Defense, and Department
of Veterans Affairs. The draft National
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
18:52 Apr 01, 2015
Jkt 235001
Pain Strategy also reflects input from
scientific and clinical experts and pain
patient advocates. It includes objectives
and plans related to key areas of pain
and pain care, including professional
education and training, public
education and communication, service
delivery and reimbursement, prevention
and care, disparities, and population
research.
I. Background
A core recommendation of the 2011
IOM Report: Relieving Pain in America
is: ‘‘The Secretary of the Department of
Health and Human Services should
develop a comprehensive, population
health-level strategy for pain
prevention, treatment, management,
education, reimbursement, and research
that includes specific goals, actions,
time frames, and resources.’’ The IOM
report highlighted specific objectives for
the strategy:
• Describe how efforts across
government agencies, including publicprivate partnerships, can be established,
coordinated, and integrated to
encourage population-focused research,
education, communication, and
community-wide approaches that can
help reduce pain and its consequences
and remediate disparities in the
experience of pain among subgroups of
Americans.
• Include an agenda for developing
physiological, clinical, behavioral,
psychological, outcomes, and health
services research and appropriate links
across these domains.
• Improve pain assessment and
management programs within the
service delivery and financing programs
of the federal government.
• Proceed in cooperation with the
Interagency Pain Research Coordinating
Committee and the National Institutes of
Health’s Pain Consortium and reach out
to private-sector participants as
appropriate.
• Involve the appropriate agencies
and entities.
• Include ongoing efforts to enhance
public awareness about the nature of
chronic pain and the role of self-care in
its management.
The Department of Health and Human
Services charged the Interagency Pain
Research Coordinating Committee
(IPRCC) with creating a comprehensive
population health-level strategy to begin
addressing these objectives.
The NINDS Office of Pain Policy, on
behalf of DHHS, requests input on the
draft National Pain Strategy.
Frm 00044
Fmt 4703
Sfmt 4703
III. Potential Responders
HHS invites input from a broad range
of individuals and organizations that
have interests in advancing the
fundamental understanding of pain and
improving pain-related treatment
strategies. Some examples of these
organizations include, but are not
limited to the following:
• Caregivers or health system providers
(e.g., physicians, physician assistants,
nurses, pharmacists)
• Researchers
• Foundations
• Health care, professional, and
educational organizations/societies
• Insurers and business groups
• Medicaid- and Medicare-related
organizations
• Patients and their advocates
• Pharmaceutical Industry
• Public health organizations
• State and local public health agencies
When responding, please self-identify
with any of the above or other categories
(include all that apply) and your name.
Anonymous submissions will not be
considered. Written materials submitted
for consideration should not exceed 5
pages, not including appendices and
supplemental documents. Responders
may submit other forms of electronic
materials to demonstrate or exhibit
concepts of their written responses. We
request that comments be identified by
section, subsection, and page number of
the draft so they may be addressed
accordingly. All comments received
before the close of the comment period
are available for viewing by the public,
including any personally identifiable or
confidential business information that is
included in a comment.
Dated: March 25, 2015.
Walter J. Koroshetz,
Acting Director, National Institute of
Neurological Disorders and Stroke, National
Institutes of Health.
[FR Doc. 2015–07626 Filed 4–1–15; 8:45 am]
BILLING CODE CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–N–0001]
Biomedical Engineering Society and
FDA Frontiers in Medical Devices:
Innovations in Modeling and
Simulation
AGENCY:
Food and Drug Administration,
HHS.
II. Information Request
PO 00000
17757
ACTION:
Notice of Public Conference
The Food and Drug Administration
(FDA) in co-sponsorship with the
E:\FR\FM\02APN1.SGM
02APN1
17758
Federal Register / Vol. 80, No. 63 / Thursday, April 2, 2015 / Notices
tkelley on DSK3SPTVN1PROD with NOTICES
Biomedical Engineering Society (BMES)
is announcing a public conference
entitled ‘‘Frontiers in Medical Devices:
Innovations in Modeling and
Simulation’’. The purpose of this
conference is to provide a forum to
discuss strategies to effectively utilize
computational modeling and simulation
in the development and evaluation of
medical devices.
Date and Time: The conference will
be held on May 18 through 20, 2015,
from 8 a.m. to 6 p.m.
Location: The public conference will
be held at the Marriott Inn and
Conference Center, University of
Maryland, 3501 University Blvd. East,
Hyattsville, MD 20783.
Contact Person: Donna R. Lochner,
Center for Devices and Radiological
Health, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 62,
Rm. 3220, Silver Spring, MD 20993,
301–796–6309, Donna.Lochner@
fda.hhs.gov.
Registration: To register for the public
conference please visit FDA’s Medical
Devices News, Events, Workshops, and
Conferences calendar at https://
www.bmes.org/meddevicesconference.
There is a registration fee to attend the
public conference to cover the expenses,
and attendees must register in advance.
The fees vary depending upon
membership status in BMES, and
include BMES members ($450), nonBMES members (includes 1 year BMES
membership) ($600), and Government
rate (BMES memberships and meals are
not included) ($250). Students will be
offered a discounted fee of $300 (BMES
member) or $350 (non-BMES member)
(includes 1 year BMES membership). A
full listing of the registration fees can be
found on the Web site listed. Although
the facilities are spacious, registration
will be on a first-come, first-served
basis.
If you need special accommodations
due to a disability, please contact Betse
Lyons at Betse@bmes.org or 301–459–
1999, 8201 Corporate Drive, Suite 1125,
Landover, MD 20785–2224, FAX: 301–
459–2444, no later than May 4, 2015.
To register for the public conference,
please visit BMES Frontiers in Medical
Devices registration page at https://
bmes.org/meddevicesregistration. Those
without Internet access should contact
Betse Lyons at 301–459–1999 to register.
SUPPLEMENTARY INFORMATION:
I. Background
The Center for Devices and
Radiological Health (CDRH) believes
that computer modeling and simulation
(M&S) has the potential to substantially
augment traditional models used to
evaluate medical devices; i.e., animal,
VerDate Sep<11>2014
18:52 Apr 01, 2015
Jkt 235001
bench, and human models, and to
accelerate and streamline the total
product life cycle of a medical device.
The use of computer models to simulate
multiple use conditions and to visualize
and display complex processes and data
can revolutionize the way medical
outcomes and medical devices are
understood. Non-proprietary computer
models could benchmark device
performance, yet lack of access to
biomedical data to construct the models
and rigorous methods to validate the
models limit their credibility and use.
To foster good science for M&S in the
medical device community, CDRH
needs to leverage the expertise in
industry and academia to advance M&S
for regulatory uses.
II. Topics for Discussion at the Public
Workshop
A large number of issues will be
discussed at the conference with the
overall theme being the application of
modeling and simulation for medical
devices at different stages in the total
product life cycle. Topics include, but
are not limited to the following:
• Model foundations for device
design ideation;
• concept development and design
optimization;
• modeling for robust design;
• design verification and validation;
• patient specific design;
• integration of modeling with
clinical studies;
• modeling and device
commercialization.
This public workshop may also form
the basis for future discussions related
to computer modeling and simulation
that could benefit U.S. public health.
Dated: March 27, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–07551 Filed 4–1–15; 8:45 am]
BILLING CODE CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
Frm 00045
Fmt 4703
Sfmt 4703
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
Mentoring Programs for HIV/AIDS
Researchers 2.
Date: March 30, 2015.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Aileen Schulte, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6140, MSC 9608,
Bethesda, MD 20892–9608, 301–443–1225,
aschulte@mail.nih.gov
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: March 27, 2015.
Carolyn A. Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–07507 Filed 4–1–15; 8:45 am]
BILLING CODE CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0481]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; New Animal Drugs
for Investigational Uses
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
SUMMARY:
National Institute Of Mental Health;
Notice of Closed Meeting
PO 00000
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\02APN1.SGM
02APN1
Agencies
[Federal Register Volume 80, Number 63 (Thursday, April 2, 2015)]
[Notices]
[Pages 17757-17758]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-07551]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2015-N-0001]
Biomedical Engineering Society and FDA Frontiers in Medical
Devices: Innovations in Modeling and Simulation
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of Public Conference
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) in co-sponsorship with the
[[Page 17758]]
Biomedical Engineering Society (BMES) is announcing a public conference
entitled ``Frontiers in Medical Devices: Innovations in Modeling and
Simulation''. The purpose of this conference is to provide a forum to
discuss strategies to effectively utilize computational modeling and
simulation in the development and evaluation of medical devices.
Date and Time: The conference will be held on May 18 through 20,
2015, from 8 a.m. to 6 p.m.
Location: The public conference will be held at the Marriott Inn
and Conference Center, University of Maryland, 3501 University Blvd.
East, Hyattsville, MD 20783.
Contact Person: Donna R. Lochner, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 62, Rm. 3220, Silver Spring, MD 20993, 301-796-6309,
Donna.Lochner@fda.hhs.gov.
Registration: To register for the public conference please visit
FDA's Medical Devices News, Events, Workshops, and Conferences calendar
at https://www.bmes.org/meddevicesconference. There is a registration
fee to attend the public conference to cover the expenses, and
attendees must register in advance. The fees vary depending upon
membership status in BMES, and include BMES members ($450), non-BMES
members (includes 1 year BMES membership) ($600), and Government rate
(BMES memberships and meals are not included) ($250). Students will be
offered a discounted fee of $300 (BMES member) or $350 (non-BMES
member) (includes 1 year BMES membership). A full listing of the
registration fees can be found on the Web site listed. Although the
facilities are spacious, registration will be on a first-come, first-
served basis.
If you need special accommodations due to a disability, please
contact Betse Lyons at Betse@bmes.org or 301-459-1999, 8201 Corporate
Drive, Suite 1125, Landover, MD 20785-2224, FAX: 301-459-2444, no later
than May 4, 2015.
To register for the public conference, please visit BMES Frontiers
in Medical Devices registration page at https://bmes.org/meddevicesregistration. Those without Internet access should contact
Betse Lyons at 301-459-1999 to register.
SUPPLEMENTARY INFORMATION:
I. Background
The Center for Devices and Radiological Health (CDRH) believes that
computer modeling and simulation (M&S) has the potential to
substantially augment traditional models used to evaluate medical
devices; i.e., animal, bench, and human models, and to accelerate and
streamline the total product life cycle of a medical device. The use of
computer models to simulate multiple use conditions and to visualize
and display complex processes and data can revolutionize the way
medical outcomes and medical devices are understood. Non-proprietary
computer models could benchmark device performance, yet lack of access
to biomedical data to construct the models and rigorous methods to
validate the models limit their credibility and use. To foster good
science for M&S in the medical device community, CDRH needs to leverage
the expertise in industry and academia to advance M&S for regulatory
uses.
II. Topics for Discussion at the Public Workshop
A large number of issues will be discussed at the conference with
the overall theme being the application of modeling and simulation for
medical devices at different stages in the total product life cycle.
Topics include, but are not limited to the following:
Model foundations for device design ideation;
concept development and design optimization;
modeling for robust design;
design verification and validation;
patient specific design;
integration of modeling with clinical studies;
modeling and device commercialization.
This public workshop may also form the basis for future discussions
related to computer modeling and simulation that could benefit U.S.
public health.
Dated: March 27, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-07551 Filed 4-1-15; 8:45 am]
BILLING CODE CODE 4164-01-P